SCHEMBL6538945

SCHEMBL6538945

O=C(CCNC(=O)OCc1ccccc1)On1nnc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ LMNA P02545 1/20 0.50
▸ GAA P10253 1/20 0.49
▸ NPC1 O15118 3/20 0.48
▸ RAB9A P51151 3/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ BRD4 O60885 1/20 0.48
▸ PRSS1 P07477 1/20 0.47
▸ PRSS2 P07478 1/20 0.47
▸ ELANE P08246 1/20 0.47
▸ PRSS3 P35030 1/20 0.47
▸ TPSAB1 Q15661 1/20 0.47
▸ TPSD1 Q9BZJ3 1/20 0.47
▸ TPSG1 Q9NRR2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.45
▸ ASAH1 Q13510 1/20 0.44
▸ SIRT2 Q8IXJ6 2/20 0.44
▸ TGM2 P21980 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3692447 0.91 HTT (0.53) HTTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL6538725 0.88 NPC1 (0.50) HTTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL5000788 0.81 NPC1 (0.52) HTTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL5352955 0.80 NPC1 (0.52) HTTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL11448781 0.77 TACR1 (0.51) SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL10625625 0.77 NPC1 (0.47) HTTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL28383136 0.77 HTT (0.68) HTTSMN1; SMN2LMNAGAAMEN1
SCHEMBL11752297 0.77 SIRT2 (0.56) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL4952678 0.77 SIRT2 (0.56) SMN1; SMN2NPC1RAB9AKMT2AALDH1A1
SCHEMBL10299926 0.77 SIRT2 (0.58) SMN1; SMN2GAANPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 — — US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 — — US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 — — EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB HTT 3050/4885SMN1; SMN2 2439/4885LMNA 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback